BRIEF: Jinxin Fertility’s business improves in fourth quarter
Fertility services provider Jinxin Fertility Group Ltd. (1951.HK) provided 7,004 in vitro fertilization (IVF) treatments to its customers in last year’s fourth quarter, up 12% from a year earlier, according to calculations based on data released by the company on Monday. The strong gain showed the company’s business is rebounding after a weak start to 2025.
After adding in the strong fourth-quarter performance, the company’s total IVF treatments for all of 2025 fell 1.4% year-on-year to 28,039, improving from a 5.2% decline in the first nine months of last year.
IVF treatments provided by the company’s Chengdu flagship rose 1.3% year-on-year to 14,070 for all 2025, equal to roughly half of its total. But treatments provided by its overseas operations fell 6.9% for the year to 4,235, as the company closed its IVF treatment center in Laos, reducing its overseas business to just the U.S.
Jinxin Fertility’s stock was up slightly at HK$2.50 in early afternoon trading on Tuesday. The shares are down about 5% over the last 52 weeks.
By Doug Young
To subscribe to Bamboo Works weekly free newsletter, click here
